IP Library Granted Patent US 9,464,321
Granted Patent B2
US 9,464,321 · App. 14/215,525 · Granted Oct 11, 2016

Methods and reagents that specifically detect, distinguish and quantify IFN-λ2 mRNA from IFN-λ3 mRNA in humans

Inventors: Grant Gallagher (Milltown, NJ); Grant E. Gallagher (Milltown, NJ); Joyce Eskdale (Milltown, NJ); Rachael Siegel (Fords, NJ)
Assignee: Medical Diagnostic Laboratories, LLC
C12Q1/6876C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,464,321
App. No.
14/215,525
Granted
Oct 11, 2016
Kind
B2
Abstract

The present invention provides a method of specifically detecting IFN-λ2 mRNA or IFN-λ3 mRNA. There is provided a qRT-PCR method specifically detecting, discriminating and quantifying IFN-λ2 and IFN-λ3 mRNA in a biological sample obtained from a human. There is provided qRT-PCR methods and primers and probes that specifically detect IFN-λ2 mRNA but not IFN-λ3 mRNA and vice versa in humans in order to detect, quantify and discriminate IFN-λ2 mRNA and IFN-λ3 mRNA.

Claims (22)

1. A method of quantifying IFN-λ2 mRNA but not IFN-λ3 mRNA in a biological sample in humans, comprising the steps of:

a) obtaining a biological sample from a human, said biological sample is suspected of having IFN-λ2 mRNA;

b) isolating mRNA from said biological sample;

c) performing a reverse transcription reaction to convert said mRNA to cDNA;

d) performing a qRT-PCR on said cDNA using an IFN-λ2-specific primer set, said IFN-λ2 specific primer set containing a forward primer and a reverse primer to yield an amplification product, wherein said forward primer consists of SEQ ID NO: 3, and said reverse primer consists of SEQ ID NO: 4, wherein said IFN-λ2-specific primer set amplifies under conditions suitable for amplification of nucleic acid sequence of IFN-λ2 mRNA and not IFN-λ3 mRNA, wherein said qRT-PCR is specific for IFN-λ2 but not IFN-λ3 with low cross-reactivity as evidenced by generation of one single peak in a dissociation curve analysis; and

e) quantifying said amplification product to determine the expression level of IFN-λ2 mRNA.

2. The method of claim 1 , wherein said biological sample is a dendritic cell.

3. The method of claim 1 , wherein said biological sample is an airway epithelial cell.

4. The method of claim 1 , wherein said biological sample is a colon cell.

5. The method of claim 1 , wherein said biological sample is a liver cell.

6. The method of claim 1 , wherein said qRT-PCR step is performed using an annealing temperature of 60° C.

7. A method of quantifying IFN-λ3 mRNA but not IFN-α2 mRNA in a biological sample in humans, comprising the steps of:

a) obtaining a biological sample from a human, said biological sample is suspected of having IFN-λ3 mRNA;

b) isolating mRNA from said biological sample;

c) performing a reverse transcription reaction to convert said mRNA to cDNA;

d) performing a qRT-PCR on said cDNA using an IFN-λ3-specific primer set, said IFN-λ3 specific primer set containing a forward primer and a reverse primer, wherein said forward primer consists of SEQ ID NO: 10, and said reverse primer consists of SEQ ID NO: 11 to yield an amplification product, wherein said IFN-λ3-specific primer set amplifies under conditions suitable for amplification of nucleic acid sequence of IFN-λ3 mRNA and not IFN-λ2 mRNA, wherein said qRT-PCR is specific for IFN-λ3 but not IFN-λ2 low cross-reactivity as evidenced by generation of one single peak in a dissociation curve analysis; and

e) quantifying said amplification product to determine the expression level of the IFN-λ3 mRNA.

8. The method of claim 7 , wherein said biological sample is a dendritic cell.

9. The method of claim 7 , wherein said biological sample is an airway epithelial cell.

10. The method of claim 7 , wherein said biological sample is a colon cell.

11. The method of claim 7 , wherein said biological sample is a liver cell.

12. The method of claim 1 , wherein said qRT-PCR step is performed using an annealing temperature of 60° C.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2015
From: GALLAGHER, GRANT; GALLAGHER, GRANT E; ESKDALE, JOYCE; SIEGEL, RACHAEL
To: MEDICAL DIAGNOSTIC LABORATORIES, LLC
Reel/Frame 036265/0703 →
Continuity (2)
Provisional Application 61791419 · Mar 15, 2013
Related Publication 20140272994A1 · Sep 18, 2014